Drug Interaction Report

MONITOR: Coadministration with inhibitors of breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of this efflux membrane transporter. However, the effect of BCRP inhibitors on the pharmacokinetics of talazoparib has not been studied in vivo.

MANAGEMENT: Caution is recommended when talazoparib is coadministered with inhibitors of BCRP. Some authorities advise that concomitant use of talazoparib with potent BCRP inhibitors such as cyclosporine should be avoided (UK). Patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of oteseconazole. When administered with a high-fat, high-calorie meal (800 to 1000 calories; 50% fat), oteseconazole peak plasma concentration (Cmax) and systemic exposure (AUC 0-72h) increased by 45% and 36%, respectively. However, no significant differences were observed with a low-fat, low-calorie meal.

MANAGEMENT: Oteseconazole should be administered with food.